Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
| ▸ | CTRC | Q99895 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106715 | 0.78 | F2 (0.33) | F2ELANECTSGCTRC | |
| SCHEMBL24658501 | 0.78 | F2 (0.33) | F2ELANECTSGCTRC | |
| SCHEMBL417344 | 0.77 | F2 (0.48) | F2ELANECTSGCTRCALDH1A1 | |
| SCHEMBL24658494 | 0.77 | F2 (0.32) | F2ELANECTSGCTRC | |
| SCHEMBL6362484 | 0.76 | F2 (0.46) | F2ELANECTSGCTRCALDH1A1 | |
| SCHEMBL24658345 | 0.74 | F2 (0.30) | F2ELANECTSGCTRC | |
| SCHEMBL14350768 | 0.74 | F2 (0.30) | F2ELANECTSGCTRC | |
| SCHEMBL24220321 | 0.72 | F2 (0.42) | F2ELANECTSGCTRCALDH1A1 | |
| SCHEMBL24742598 | 0.72 | F2 (0.33) | F2ELANECTSGCTRC | |
| SCHEMBL6343935 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363632-A1 | Compounds Useful for Treating Liver Diseases | ABIONYX PHARMA SA (FR) | 2022-11-17 | — | — | US | disclosed |
| US-20210300890-A1 | Compounds Useful for Treating Liver Diseases | ABIONYX PHARMA SA (FR) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300890-A1 | Compounds Useful for Treating Liver Diseases | SLC10A1, FABP1, CPT1A | F2 467/4885ELANE 580/4885CTSG 937/4885 |
| US-20220363632-A1 | Compounds Useful for Treating Liver Diseases | SLC10A1, FABP1, CPT1A | F2 467/4885ELANE 580/4885CTSG 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.